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Abstract: 5′ AMP-activated protein kinase (AMPK) is considered the master metabolic 
regulator in all eukaryotes, as it maintains cellular energy homeostasis in a variety of tissues, 
including the brain. In humans, alterations in AMPK activity can lead to a wide spectrum of 
metabolic disorders. The relevance of this protein kinase in the pathogenesis of diabetes and 
metabolic syndrome is now well established. On the contrary, correlations between AMPK and 
brain physiopathology are still poorly characterized. The aim of this review is to summarize 
and discuss the current knowledge about the prospective involvement of AMPK in the onset 
and the progression of different neurological diseases.
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Introduction
The maintenance of energy homeostasis is guaranteed by the tight regulation of 
molecular and functional mechanisms involved in energy intake and expenditure. The 
AMP-activated protein kinase (AMPK) is a sensor of AMP:ATP ratio and mediates 
adaptive changes as a function of low energy conditions. AMPK is considered the 
metabolic regulator of the whole organism, and it has become the leading factor in 
the study of obesity, diabetes, cachexia, and other metabolic disorders. However, 
during the last decade, increasing evidence sustains a pivotal role for AMPK also in 
the physiopathology of the central nervous system (CNS). AMPK is implicated in 
several neuronal aspects, such as neuronal proliferation and differentiation, synaptic 
connectivity, and neuroprotection. Thus, alterations in AMPK could easily lead to the 
onset of different neurological and neurodegenerative diseases.
AMPK: a pivotal metabolic regulator of the whole 
organism
Structure and regulation
In most species, AMPK exists as a heterotrimeric protein complex, containing α, β, 
and γ subunits in equal stoichiometry. The α subunit is responsible for the catalytic 
kinase activity, whereas the β and γ are regulatory subunits. In particular, mammalian γ 
subunits contain four cystathionine-β-synthase (CBS) domains, which occur as tandem 
pairs and function as nucleotide-binding sites for AMP or ATP.1 When intracellular 
ATP levels are low, AMP or ADP directly and mutually bind to the γ regulatory subunits 
of AMPK, thus inducing a conformational change that leads to AMPK activation.2,3 
High AMP levels also protect AMPK from dephosphorylation events operated by the 
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major classes of serine/threonine phosphatases (PP1, PP2A, 
and PP2Cα). The activatory phosphorylation of AMPK is 
mainly mediated by liver kinase B1 (LKB1), which phos-
phorylates the α catalytic subunit at Thr172.4 However, 
several studies have demonstrated that AMPK can be also 
phosphorylated on Thr172 in response to intracellular cal-
cium levels by calcium/calmodulin-dependent protein kinase 
kinase 2 (CAMKK2).5–8 (For extensive review, see works by 
Hardie5 and Moussa and Li8).
There are two genes encoding the α catalytic subunits 
(α1 and α2), two β genes (β1 and β2), and three γ genes (γ1, 
γ2, and γ3). Some of these isoforms display a tissue-specific 
expression pattern, and several experimental data also high-
light functional distinctions for the two catalytic α subunits, 
which reflect in AMP- and LKB1-responsiveness and nuclear 
localization. AMPKα2 isoform is particularly abundant in the 
nucleus, even though AMPKα1 is able to translocate to the 
nucleus under distinct and peculiar conditions.9,10 Moreover, 
the myristoylation of the β isoforms is an essential prerequisite 
for AMPK activation and its localization to membranes.11
Even though all the AMPK subunits are expressed in the 
brain, interesting findings underlie a specific distribution pat-
tern of the various subunit isoforms among cell types in the 
CNS. For instance, the α2 represents the dominant catalytic 
subunit in neurons. On the other hand, α subunits are not 
generally expressed in glial cells at basal conditions, but only 
in activated astrocytes. The γ1 subunit is mainly expressed in 
neurons but absent in astrocytes, and the amount of β1 and 
β2 subunits also differs according to the brain cell type (for 
extensive review, see Turnley et al12).
AMPK orchestrates autophagy  
and cell proliferation
Eukaryotic cells adaptively respond to low-nutrient condi-
tions by blocking cell growth and proliferation. These events 
are mediated by AMPK through the activation of p53, the 
inhibition of the mammalian target of rapamycin (mTOR) 
complex 1 (mTORC1), and the induction of autophagy. 
The inhibition of cell-cycle progression-induced by AMPK 
occurs via MDMX phosphorylation on Ser342, which leads 
to an increased binding of MDMX to 14-3-3. The subsequent 
inactivation of MDMX is responsible for the enhanced 
stability and activation of p53, which provokes a cell-cycle 
checkpoint.13
Beyond effects on p53, AMPK directly phosphorylates 
the tumor suppressor tuberous sclerosis complex 2 (TSC2) 
thus stimulating its GAP activity toward Rheb, which in 
turn leads to the inactivation of mTORC1 and the  inhibition 
of cell proliferation.8,14 AMPK also blocks the positive 
trophic effects of mTORC1 through the direct phosphory-
lation of regulatory associated protein of mTOR (raptor) 
(Figure 1).15
Besides the regulation of cell growth and proliferation, 
mTORC1 suppresses the autophagic flux through the inhibi-
tion of uncoordinated 51-like kinase 1 (ULK1) complex.16 
Autophagy is required for the breakdown of cellular organ-
elles and the recycling of cellular components under nutrient 
deprivation, as well as for the selective clearance of damaged 
organelles. In contrast to the inhibitory regulation operated by 
mTORC1, a variety of experimental evidence demonstrated 
that AMPK promotes autophagy by direct phosphorylation 
of ULK1 at several serine residues (eg, Ser317, Ser555, 
and Ser777).17,18 AMPK-dependent stimulation of ULK1 
complex seems to appear as a universal event for the induc-
tion of autophagy, as it occurs under different conditions 
such as nutrient starvation, hypoxia, and drug administration. 
This route of activation results in the promotion of not 
only nonselective autophagy (known as bulk autophagy) 
but also selective autophagy: for instance, AMPK triggers 
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Figure 1 AMPK modulates cell-cycle progression and cell growth.
Notes: Cell growth inhibition is mainly achieved by regulating one of the most 
well-known anabolic pathways, which involves mTORC1. AMPK activates TSC1/2 
complex, leading to the downregulation of mTORC1, composed by mTOR itself and 
the associated protein, raptor. AMPK is also able to inactivate mTORC1 through the 
direct phosphorylation of raptor. in addition, AMPK blocks the activity of MDMX, 
thus leading to the stabilization of p53 and the subsequent cell-cycle arrest. inhibitory 
phosphorylations are shown in red and activating phosphorylations in blue.
Abbreviation: AMPK, AMP-activated protein kinase.
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mitophagy through the phosphorylation of ULK1 during stress 
conditions, and this pathway is also required for the clearance 
of damaged mitochondria in physiopathological states.19–24 
In addition, recent data showed that AMPK phosphorylates 
Beclin1 at Ser91/94, and this event is essential for the induc-
tion of autophagy in nutrient stress response.25 An interesting 
study published by Sanchez et al sustains that AMPK also 
determines, at least in skeletal muscle, the FoxO3-dependent 
increase of autophagy-related proteins, such as LC3B, GABA-
RAPL1, and Beclin1.26 Another research supports these 
findings, since AMPK directly activates FoxO3 transcription 
through the phosphorylation of different serine residues (eg, 
Ser413, Ser588).27 Collectively, these data highlight that 
AMPK drives autophagy at multiple levels (Figure 2).
AMPK maintains energy homeostasis 
through short- and long-term regulation 
of metabolic targets
AMPK was originally discovered as the main protein kinase 
involved in the short-term modulation of key enzymes con-
trolling fatty acid and cholesterol biosynthesis. In particular, 
AMPK was found to be responsible for the rapid regulation 
of acetyl-CoA carboxylase (ACC) and HMG-CoA reductase 
(HMGR), as the inhibitory phosphorylation mediated by this 
kinase is able to strongly suppress the activity of both the 
enzymes.28,29
In highly specialized cells of metabolic organs, such as 
skeletal muscle and adipose tissue, AMPK regulates glucose 
metabolism promoting the phosphorylation of AS160 and 
Tbc1d1 and the subsequent binding to 14-3-3. These events 
lead to an enhancement of GLUT4 translocation on the cell 
membrane.30 In addition, AMPK drives lipid mobilization 
by directly phosphorylating hormone-sensitive lipase (HSL) 
and adipocyte triglyceride lipase (ATGL).31,32 Recently, 
these mechanisms have been shown to be involved not only 
during homeostasis maintenance in physiological conditions 
but also in the development of metabolic disorders such as 
cancer-associated cachexia.33
The adaptive changes in energy homeostasis induced 
by AMPK are not limited to the short-term regulation of 
enzymes, as this kinase orchestrates a profound metabolic 
reprogramming through transcriptional control. For instance, 
AMPK phosphorylates a variety of transcriptional factors 
and cofactors, such as PGC1α, p300, histone deacetylase 5 
(HDAC5), and sirtuin1, thus leading to the long-term regu-
lation of genes involved in gluconeogenesis, lipogenesis, 
and mitochondrial biogenesis (for details, see Mihaylova 
and Shaw19). Of note, AMPK also suppresses the activation 
of SREBP1 and SREBP2. The inhibitory phosphorylation 
mediated by AMPK is a pivotal prerequisite to prevent the 
proteolytic processing and activation of SREBPs. SREBPs 
are crucial transcription factors involved in the regulation 
of lipogenic genes, such as ACC and HMGR.34 As a result, 
AMPK controls lipid metabolism regulating both the activity 
and the protein levels of enzymes implicated in fatty acid 
and cholesterol biosynthesis (Figure 3).
Physiological roles of AMPK  
in the CNS
AMPK regulates brain cell metabolism, 
proliferation, and morphology
Even though the brain constitutes 2% of the total body weight, it 
utilizes 50% of the entire glucose supply. The energy consump-
tion by brain cells is very high and, unlike other peripheral cells, 
neurons use only glucose as a source of energy. As neurons are 
not able to synthesize and store a sufficient amount of glycogen, 
it is indispensable to ensure themselves a constant and con-
tinuous source of glucose.35 During the last few years, several 
research groups highlighted a crucial role for AMPK in the 
regulation of energy production and consumption in neurons. 
Synaptic activation is followed by a number of molecular and 
cellular events characterized by high energy consumption, such 
as sodium pump activity, neurotransmitter receptor transloca-
tion/recycling, synaptic transport, cytoskeleton remodeling, 
and metabolic processes. In the light of these observations, 
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Figure 2 AMPK drives autophagy through short- and long-term mechanisms.
Notes: AMPK directly phosphorylates and activates proteins involved in the 
initiation and nucleation steps of autophagy, such as ULK1 and Beclin1. The 
permissive action of AMPK on autophagy is also mediated by the inhibition of 
mTOR pathway. Furthermore, AMPK phosphorylates FoxO3, leading to increased 
transcription of autophagy-related genes. inhibitory phosphorylations are shown in 
red and activating phosphorylations in blue.
Abbreviation: AMPK, AMP-activated protein kinase.
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it was demonstrated that the decrease in ATP levels follow-
ing glutamate stimulation is able to strongly phosphorylate 
AMPK, and the activation of glutamate transmission enhances 
the translocation of the glucose transporter GLUT3 on cell 
surface. Notably, the increase of GLUT3 on cell membrane 
is mediated by AMPK, as the pharmacological inhibition or 
the knockdown of this kinase is able to completely prevent the 
glutamate-induced GLUT3 translocation.36
In addition to glucose metabolism, other studies indicated 
that AMPK acts as a key regulator of mitochondrial function 
and biogenesis in neurons. In Neuro2a cell line, AMPK activa-
tion by resveratrol determines an increase in the transcripts of 
the mitochondrial protein marker Mitofusin 2, and a rise in the 
master regulators of mitochondrial biogenesis, PGC-1α and 
mitochondrial transcription factor A (mtTFA). AMPK inhibi-
tion suppresses the transcription of these mitochondrial-related 
proteins, further sustaining that AMPK exerts a pivotal role in 
the regulation of mitochondrial metabolism in neurons.37,38
Besides the direct regulation of metabolism in neurons, 
AMPK has been shown to be involved in neurodevelopmental 
processes. For instance, AMPK maintains the genomic integ-
rity during neural progenitor cell division in Drosophila, and 
any interference with the activity of this kinase provokes 
embryonic lethality.39 This study corroborates the finding that 
the ablation of AMPK β1 subunit leads to a severe reduction 
in the number of neurons and oligodendrocytes, as well as 
alterations in astrocyte proliferation in mice. Indeed, defects 
in AMPK functionality induce aberrant proliferation and 
increased apoptosis of neural stem cell progenitors (NPCs). 
The effects of AMPK on NPC proliferation and viability are 
exerted through direct phosphorylation of Rb protein, whose 
activation is required for the normal development of CNS.40
Increasing evidence also suggests that AMPK plays 
an important role in the control of cell polarization under 
energy-lacking conditions. As an instance, AMPK modulates 
the establishment of initial neuronal polarity by affecting the 
processes at the root of axogenesis.41 In addition, a recent 
work sustains that AMPK regulates neuronal development 
during dendrite outgrowth and branching. At molecular 
level, the effects on neuronal architecture are induced by 
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Figure 3 AMPK controls cell metabolism.
Notes: AMPK phosphorylates/activates HSL and ATGL, thus leading to increased lipolysis. On the contrary, the inhibitory phosphorylations on HMGR and ACC are 
responsible for the reduction in lipid biosynthesis. This kinase also affects the transcription of lipogenic genes through the direct phosphorylation of SReBP transcription 
factors. AMPK regulates mitochondrial biogenesis, as it activates PGC1α and the subsequent transcription of PPAR target genes. in addition, AMPK controls the membrane 
translocation and the protein expression of GLUT4 by inhibiting Rab GTPase activating proteins (AS160 and Tbc1d1) and HDAC5, respectively. inhibitory phosphorylations 
are shown in red and activating phosphorylations in blue.
Abbreviation: AMPK, AMP-activated protein kinase.
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the AMPK-dependent suppression of both mTOR and Akt 
signaling pathways.42
In adult brain, AMPK drives the cellular events involved 
in the aging process. An elegant study performed in 
Drosophila demonstrated that the activation of neuronal 
AMPK determines a delay in systemic aging and prolongs life 
span. These outcomes are mediated by the AMPK-dependent 
activation of autophagy and the synergic reduction of insulin-
like peptide signaling.43
Hypothalamic AMPK controls food intake 
and body weight
Metabolic diseases are regarded as a major health problem 
in many Western countries. Generally, they are caused by 
the lack of physical activity and are strictly associated to the 
presence of food intake-related disorders. From a pathophysi-
ological point of view, metabolic diseases are characterized 
by obesity, insulin resistance, and several atherogenic signs, 
leading to disruption in energy homeostasis.44
Whole-body energy balance is guaranteed not only by the 
functionality of high metabolic peripheral tissues such as liver, 
skeletal muscle, and adipose tissue, but also by the control of 
the CNS. The hypothalamus represents the main brain area 
involved in regulating food intake and energy expenditure, 
and it is organized into several structural and functional 
nuclei, including the arcuate nucleus (ARC), the paraven-
tricular nucleus (PVN), the dorsomedial nucleus (DMN), the 
ventromedial nucleus (VMN), and the lateral hypothalamic 
area. The majority of these hypothalamic regions are involved 
in the production and secretion of orexigenic and anorectic 
neuropeptides that affect food intake and energy homeostasis. 
For instance, the orexigenic neuropeptides agouti-related 
protein (AgRP) and neuropeptide Y (NPY), as well as the 
anorectic neuropeptide α-melanocyte-stimulating hormone 
(MSH) are synthesized by the ARC.45,46 On the other hand, 
the orexigenic neuropeptides melanin-concentrating hormone 
(MCH) and orexins are produced by the lateral hypothalamic 
area.45,47 In addition, both the hypothalamic regions possess 
the capability to synthesize the anorexigenic neuropeptide 
cocaine-amphetamine regulated transcript (CART).48
During the last few years, a variety of hormones have been 
identified as powerful modulators of energy balance.49 In this 
context, AMPK exerts a pivotal role in nutritional regulation and 
energy homeostasis, as this kinase orchestrates the hormonal 
signaling pathways required for the production and the release 
of hypothalamic orexigenic and anorectic neuropeptides.50–52
The orexigenic hormones induce the activation of 
hypothalamic AMPK. Specifically, cannabinoids exert their 
permissive effects on food intake by activating cannabinoid 
receptors expressed in the VMN, whereas ghrelin, secreted 
by the gastric mucosa, binds to receptors expressed in both 
VMN and ARC.53,54 Different findings demonstrated that a 
rise in ghrelin levels is associated with an increase in food 
intake and body weight.55,56
At molecular level, the ghrelin-dependent increase of 
intracellular Ca2+ triggers CAMKK2 activity, which in 
turn enhances AMPK phosphorylation and the subsequent 
activity of AgRP/NPY and pro-opiomelanocortin (POMC) 
neurons.57,58 Similar orexigenic effects are also elicited 
by adiponectin. This adipocyte-secreted hormone mimics 
the outcomes induced by ghrelin through the activation of 
hypothalamic AMPK.59 However, the molecular mechanisms 
linking adiponectin and AMPK modulation are still not 
completely elucidated.
The anorexigenic hormones leptin and insulin control 
food intake and body weight by suppressing hypothalamic 
AMPK. The effects promoted by leptin are mediated through 
the modulation of neuropeptides in the ARC and PVN, whereas 
multiple hypothalamic regions are affected by insulin. An 
interesting study demonstrated that MC4 transduction path-
way is required for AMPK inhibition by these hormones, and 
the expression of the constitutively active AMPKα2 isoform 
completely prevents the effects on food intake and body weight 
elicited by leptin.60 Tri-iodothyronine (T3) represents another 
anorexigenic hormone able to regulate the whole-body energy 
balance through the inhibition of AMPK in neurons located 
at the VMN. As for leptin, T3 determines norepinephrine/
epinephrine release from sympathetic nerves, which stimu-
lates fatty acid mobilization from white adipose tissue and 
heat production in brown adipose tissue.61 AMPK inhibition 
mediates the effects of anorectic hormones at least by two 
different mechanisms: the former involves the activation of 
ACC and the subsequent increase in fatty acid biosynthesis, 
which culminates in the translocation of fatty acids across the 
mitochondrial membrane; the latter is related to the activation 
of mTOR and the consequent phosphorylation of p70S6 kinase 
(p70S6K) and 4EBP1. The modulation of these pathways leads 
to the suppression of orexigenic AgRP/NPY neurons and the 
activation of anorectic POMC/CART neurons.60,62–65
Pathological involvement of AMPK 
in neurological conditions
AMPK in neurodegenerative disorders
Given the importance of AMPK in regulating stress responses, 
it is not surprising that dysfunctions of AMPK signaling are 
associated with several brain diseases including Alzheimer’s 
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disease (AD), Huntington’s disease (HD), and Parkinson’s 
disease (PD). Here, we summarize the current knowledge 
about the pathophysiological roles of AMPK in regulating 
neuronal survival during neurodegenerative disorders.
AMPK in AD
AD is the most common form of dementia, characterized by 
progressive neurodegeneration, particularly affecting cortical 
and hippocampal brain regions. Histopathological features of 
AD are senile plaques, composed of β-amyloid (Aβ) peptide 
polymers, and intracellular neurofibrillary tangles, formed 
by hyperphosphorylated Tau protein.66
AD has been identified as a protein misfolding disease 
and is caused by accumulation of abnormally folded Aβ in the 
brain.67 Aβ peptides originate from the proteolysis of amyloid 
precursor protein (APP) – amyloidogenic pathway – by the 
sequential enzymatic actions of beta-site amyloid precur-
sor protein-cleaving enzyme 1 (BACE-1, or β-secretase) 
and a protein complex with presenilin 1 at its catalytic core 
(γ-secretase).68,69
AMPK has been identified to play an important role in the 
development of AD. This hypothesis was initially supported 
by different evidence highlighting the hyperphosphorylation 
of AMPK in the brains of both AD patients and AD mouse 
models.70–72 Moreover, a different AMPK subcellular localiza-
tion is present in the brains of AD patients when compared 
with control subjects.70 It is now well established that AMPK 
is a key regulator of Aβ generation. Vingtdeux et al showed 
that the activation of AMPK by resveratrol lowers extracel-
lular Aβ accumulation.73 The same research group demon-
strated that this polyphenol inhibits the AMPK target mTOR, 
triggering autophagy and lysosomal degradation of Aβ.
Studies conducted on cultured rat cortical neurons 
revealed that Aβ production is significantly reduced after 
stimulation with the AMPK activator 5-aminoimidazole-4-
carboxamide-1-d-ribofuranoside (AICAR). On the contrary, 
Aβ peptide levels are increased when AMPKα2 is knocked 
out, thus indicating the crucial involvement of AMPK in 
amyloidogenesis.74 AMPK controls Aβ generation through 
the modulation of neuronal cholesterol and sphingomyelin 
levels, which regulate APP distribution in lipid rafts.67 In 
addition, leptin-induced AMPK activation is associated with 
a reduction in Tau phosphorylation.75
Despite these findings, other evidence sustains an opposite 
role for AMPK in AD. Interestingly, the activation of AMPK 
by metformin is protective in females but increases memory 
dysfunction in males, suggesting a sex-divergent cognitive 
effect in a murine model of AD.76 Moreover, chronic treatment 
of AD mice with the same compound was reported to enhance 
the generation of Aβ via the upregulation of β-secretase at 
transcriptional level.77 Noteworthy AMPK inhibitor com-
pound C (CC) is able to correct Aβ-induced inhibition of 
long-term potentiation (LTP) and the enhancement of long-
term depression (LTD). Similarly, LTP impairments in APP/
PS1 transgenic mice are improved by CC treatment.78
AMPK in HD
HD is an age-related neurodegenerative disorder, character-
ized by motor and cognitive impairment, and caused by a 
CAG trinucleotide expansion in exon 1 of the Htt gene. When 
the number of CAG repeats is 36 or more, the translated 
polyglutamine-expanded Htt protein interferes with the nor-
mal functions of cellular machinery and causes cytotoxicity. 
The major characteristic of HD is the selective loss of neurons 
in the neostriatum, nigrostriatal tract, and cortex, which leads 
to movement disorders, dementia, and eventual death.79
Recent research showed that mitochondria and several key 
molecular players in energy homeostasis are altered during 
HD progression. Notably, mutated Htt (mHtt) forms aggre-
gates on mitochondrial membranes. This aberrant associa-
tion impairs calcium homeostasis and triggers Ca2+-induced 
oxidative stress, decreases the activity of mitochondrial 
respiratory complexes (II and III), and alters mitochondrial 
fission and fusion, globally disrupting the neuronal energy 
homeostasis. In this scenario, AMPK could represent one 
of the leading actors in modulating metabolic events.80,81 
Indeed, AMPK was found to be abnormally activated in the 
striatum of a transgenic mouse model of HD (R6/2).82 Ju et al 
highlighted that the activation of AMPKα1 in striatal neurons 
is closely associated with mHtt-induced cell death.79 The 
induction of neurotoxicity requires the nuclear translocation 
of AMPKα1 to suppress the expression of the survival gene 
Bcl2 in striatal neurons.79 Furthermore, AMPK activation by 
AICAR in HD mice induces neuronal apoptotic activation 
and worsens motor function.79,81 The same research groups 
showed that the induction of cAMP/PKA signaling reduces 
AMPK activity, thus preventing the detrimental effect of 
AMPKα1 in the nuclei of striatal neurons.
AMPK in PD
PD is the most common neurodegenerative movement disor-
der and the second most common neurodegenerative disease 
after AD. Clinically, it is characterized by tremor, rigidity, and 
bradykinesia, and pathologically by the loss of dopaminergic 
neurons in the substantia nigra. During the last few years, 
a plethora of studies identified different genes involved in 
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familial forms of PD, and implicated aberrant mitochon-
drial homeostasis as one of the key contributors to PD.83 
Among the disease-associated genes, recessive mutations in 
several genes such as α-synuclein, DJ-1, PINK, parkin, and 
dominant mutations in LRRK2 (especially the G2019S vari-
ant) are directly or indirectly associated with mitochondrial 
dysfunction in PD.84
In this pathology, AMPK activation is similarly a double-
edged sword, promoting or aggravating neurodegeneration 
under different circumstances.85 Indeed, AMPK exerts a 
neuroprotective role as demonstrated in mice treated with 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 
which represents the most common experimental model used 
to investigate the pathogenesis of PD. Recent findings sustain 
that AMPK is activated by MPTP in mice and MPP(+) in SH-
SY5Y cells, and the inhibition of AMPK by CC resulted in 
an increase of neuronal cell death.86 In addition, AMPK acts 
with parkin in a functionally converging manner to guarantee 
the quality control of organelles.85 Hence, the activation of 
AMPK may prevent neuronal cell death and play a role as a 
survival factor in PD.
In contrast to these findings, Kim et al described that poly 
(ADP-ribose) polymerase-1 (PARP-1) promotes ATP deple-
tion and the subsequent activation of AMPK, which mediates 
the degeneration of dopaminergic neurons.87
impact of AMPK on cancer cell fate  
and brain tumors
A variety of tumor types, including brain tumors, are char-
acterized by uncontrolled and rapid cell growth. In order to 
sustain the enhanced rate of mitosis, tumor cells undergo 
profound changes in their metabolism, a phenomenon known 
as “Warburg effect”.88
It has been demonstrated that AMPK regulates cell growth 
arrest and cell death interacting both with mTOR and p53 in 
normal cells. Furthermore, the modulation of AMPK repre-
sents an important prerequisite for the induction and mainte-
nance of cell proliferation under abnormal nutrient conditions 
in cancer cells. The role of AMPK in brain tumors is still 
poorly understood and controversial hypotheses have been 
proposed. Glioma represents a large group of common brain 
tumors that comprises glioblastoma and astrocytoma.89 Rios 
et al observed that AMPK is hyperactivated both in astrocytes 
expressing HRasV12 (common mutation in human astrocy-
toma) and in glioblastoma cell lines compared to control cells. 
High phospho-AMPK levels were also detected in samples 
derived from glioblastoma patients, whereas normal brain 
tissue was completely negative. CC treatment and the genetic 
deletion of AMPK lead to a strong decrease of cell prolifera-
tion and to a reduction of Rb phosphorylation, suggesting that 
AMPK could play a critical role in tumor growth by regulating 
Rb and, consequently, cell-cycle progression.90 Furthermore, 
it has been shown that AMPK activity is necessary to provide 
metabolic support during early stages of tumor growth.91 
The relevance of AMPK in oncology has been demonstrated 
not only for cell growth but also for cell migration. Indeed, 
AMPK inhibition antagonizes the ghrelin-mediated migra-
tion of rat C6 and human U251 glioma cells, suggesting that 
AMPK activation is an obligatory event in ghrelin-induced 
glioma migration.92 In a retrospective clinical analysis, it 
has been revealed that high-grade human glioma expresses 
higher levels of AMPKα2 subunit if compared to low- and 
mid-grade gliomas. The α2 subunit is selectively induced in 
hypoxic conditions and significantly contributes to vascular 
endothelial growth factor (VEGF) expression in human 
glioma cells, thus improving neoangiogenesis and underlying 
the pivotal role of AMPK in glioma progression.93 In addition, 
the resistance to antiangiogenic therapies in glioblastoma 
may depend on the autophagic flux induced by the activation 
of hypoxia-inducible factor-1α (HIF-1α)/AMPK axis after 
hypoxia and lack of nutrients.94 Even though all these data 
sustain a protumor effect of AMPK, other researchers suggest 
that AMPK acts as an oncosuppressor. Guo et al showed that 
AMPK activation by AICAR blocks EGFR-activated glioma 
proliferation through the modulation of mTORC1 signaling 
and lipid biosynthesis.95 The antitumor effects of AMPK were 
also demonstrated by the induction of apoptosis in mouse 
astrocytoma cell line following AICAR administration.96 This 
finding corroborates the outcomes induced by metformin, 
which is able to inhibit tumor cell growth and to enhance the 
sensitivity of glioblastomas to chemotherapy.97
The use of different biological models (ie, different cell 
lines or mouse models, and different cancer mutations) may 
lead to the contrasting evidence about the prospective role of 
AMPK in glioma. In addition, AMPK activators or inhibitors 
may have AMPK-independent effects on cancer cells, making 
it more difficult to dissect the specific role of this kinase 
in brain tumors.98,99 Furthermore, AMPK could not show 
a unique behavior; conversely, it may play a protumoral or 
antitumoral role depending on the energetic and the genetic 
status of the tumor.
Another aggressive brain tumor is neuroblastoma, 
the most common extracranial solid tumor in children.100 
Although only little knowledge is available about its 
role in neuroblastoma, AMPK is believed to act as an 
oncosuppressor. In particular, AMPK activity may lead to 
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apoptosis via p38MAPK/p53 pathway in neuro2a and SH-SY5Y 
neuroblastoma cell lines.101,102 However, research in this field 
is still limited and more detailed analysis will be necessary 
to specifically assess the involvement of AMPK in the onset 
and progression of neuroblastoma.
AMPK regulation in stroke
Ischemic stroke is one of the most frequent leading causes 
of death worldwide.103 Recently, different studies showed that 
AMPK is rapidly activated in an energy-deprived status such 
as that which follows a stroke. Ischemic stroke promotes the 
activation of oxidative and cell death pathways, leading to 
cellular energy imbalance, that increases the phosphorylation 
of AMPK in an attempt to restore ATP levels through the 
enhancement of glycolysis and fatty acid oxidation, increment 
of glucose transport, and inhibition of glycogen synthesis.104–106 
Thus, AMPK plays a crucial role in regulating ischemic stroke 
phenotype, but it is unclear whether its activation would be 
detrimental or beneficial. In vivo studies using the transient 
middle cerebral artery occlusion (MCAO) model in mice 
have shown that AMPK activation is damaging, because the 
pharmacological inhibition of AMPK with CC causes a reduc-
tion in stroke volume, whereas the treatment with AICAR 
leads to a more severe injury, suggesting that inactivation 
of AMPK during ischemia may be neuroprotective.107 The 
mechanisms through which acute AMPK activation exac-
erbates stroke injury are still unclear. It has been suggested 
that AMPK activation enhances astrocytic glycolysis which 
leads to progressive lactic acidosis, exacerbating lactate accu-
mulation, and inhibits the ability of neurons to use lactate as 
an energy source, contributing to neuronal death. Moreover 
AMPK activation is responsible for the aberrant neuronal 
nitric oxide synthase activity, which in turn produces per-
oxynitrite, the strongest oxidizing agent. These data support 
the hypothesis that AMPK activation in the acute phase of 
stroke is associated with injury.108 To corroborate the idea that 
AMPK activation is harmful in ischemic stroke, preclinical 
studies demonstrated that mice deficient in AMPKα2 have 
less injury and show a reduced total infarct volume compared 
with wild-type littermates in an MCAO reperfusion model. 
AMPKα1-knockout mice have no difference in injury com-
pared with wild-type mice, suggesting that AMPKα2 isoform 
plays a more significant role in the damaging response of 
AMPK activation in ischemic brain.109 On the contrary, recent 
clinical trials report that metformin significantly reduces the 
risk and incidence of stroke by actions that are independent of 
its glucose-lowering effects.110–112 The chronic treatment with 
metformin offers potent neuroprotective effects similar to pre-
conditioning, a phenomenon by which exposure to sublethal 
ischemia stimulus leads to protection of the organism from 
subsequent severe ischemic insults.113,114 In particular, it was 
observed that chronic metformin treatment is able to signifi-
cantly downregulate stroke-mediated brain injury, increase 
phospho-AMPK levels, reduce lactate formation, improve 
infarct damage, enhance angiogenesis, and alleviate inflam-
matory responses by a negative feedback mechanism, blunting 
ischemia-induced AMPK activation.115,116 Interestingly, only a 
chronic metformin treatment is beneficial for the prevention 
of ischemic disease and the change from a chronic to an acute 
regimen worsens ischemic injury and functional outcome 
in otherwise healthy animals, by enhancing AMPK activity 
and lactic acidosis.115 In addition, a recent study showed that 
acute metformin treatment in diabetic rats worsens the infarct 
size and caused significant neurological deficiencies if com-
pared to untreated diabetic animals.117 Thus, metformin has 
negative effects on the severity of neurovascular injury when 
used acutely, but chronic treatment is protective against fatal 
cerebral ischemia. The explanation of these divergent results 
may be dependent on the extent of AMPK manipulation in 
vivo, on timing and amount of its activation, and on different 
animal strains and models.118 As ischemic stroke is a condi-
tion of severe energy depletion and AMPK is a master energy 
regulator, future investigations are needed to provide new 
information about the therapeutic potential of acute and/or 
chronic AMPK modulation in stroke.
AMPK in genetic and chromosomal 
disorders
Although a direct involvement is still unclear, different 
genetic and chromosomal aberrations strongly suggest a role 
for AMPK in the development of mental disabilities in genetic 
disorders. Mutations in the PRKAG2 gene (AMPKγ2 subunit) 
have been associated with hereditary cardiac arrhythmias 
(Wolff–Parkinson–White syndrome, OMIM 194200), 
familial hypertrophic cardiomyopathy (OMIM 600858), and 
glycogen storage disease of the heart (OMIM 261740).119–121 
Interestingly, a polymorphism in the PRKAG2 gene has been 
also linked to cognitive impairments in elderly people.122
PRKAB2 gene (AMPKβ2 subunit), which maps on 
chromosome 1q21.1, is included in chromosomal rearrange-
ments causing the chromosome 1q21.1 deletion (OMIM 
612474) and duplication (OMIM 612475) syndromes. 
Deletions or duplications (copy number variations [CNVs]) 
of 1q21.1 chromosomal region have been associated with 
variable phenotypes, which include intellectual disability 
and/or autism, schizophrenia, congenital heart anomalies, 
dysmorphic features, or a normal phenotype.123 The crucial 
role of AMPK in brain function is particularly empathized 
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in 1q21.1 CNV carriers, as they manifest some form of 
learning disabilities.123 Notably, AMPK inhibits the mTOR 
pathway, which is required for the modulation of learning 
and memory processes.124
The involvement of AMPK in brain functioning is further 
supported by recent studies demonstrating that 1q21.1 CNVs 
(candidate gene PRKAB2) were most frequently associated 
with schizophrenia.125,126
It has been shown that AMPKβ2 protein levels change in 
concordance with the 1q21.1 copy number state in patient-
derived lymphoblastoid cell lines (LCLs).123 This imbalanced 
expression affects AMPK activity, as the basal levels of 
phospho-AMPKα in both 1q21.1 Del and Dup expressing 
cells are significantly different in comparison to wild-type 
cells.123 Furthermore, the AICAR-induced phosphorylation of 
the AMPK substrates ACC and raptor is suboptimal in 1q21.1 
Del and Dup LCLs with respect to wild type, but it is more 
evident in the 1q21.1 Del-containing cells, demonstrating that 
the reduced availability of a regulatory β-isoform could affect 
AMPK activity to a greater extent than its overabundance.123
The critical role of AMPK in the CNS could also help to 
elucidate the mechanisms that contribute to altered neuronal 
function in patients affected by other genetic diseases, such 
as TSC (OMIM 191100 and 613254). TSC is an autosomal 
dominant disorder characterized by hamartomas in multiple 
organs and neurological manifestations such as seizures, 
hyperactivity and aggression, intellectual disability, or learn-
ing problems.20 TSC is caused by mutations in the TSC1 
or TSC2 genes, leading to the disruption of TSC1–TSC2 
intracellular protein complex and to the hyperactivation 
of mTORC1.127 It was reported that TSC1/2 deficiency 
reflects in a reduced autophagy because of the inactivation 
of ULK1 operated by mTORC1 in non-neuronal cells. On 
the contrary, a recent study demonstrated that TSC1/2 loss 
in neurons determines an enhanced induction of autophagy 
via AMPK-dependent phosphorylation of ULK1 at Ser555. 
Thus, despite the concomitant inhibitory effect of mTORC1 
on ULK1 activity, AMPK seems to be the dominant modu-
lator of autophagy in brain cells.20 As a consequence, the 
accumulation of p62 and autolysosomes could contribute to 
the altered neuronal homeostasis in TSC disease.
Conclusion
The fine regulation of energy intake and expenditure is of 
great importance for maintaining the integrity of physiological 
processes in almost all eukaryotic cells. AMPK is the master 
regulator of metabolic stress and mediates pivotal adaptive 
changes as a function of nutrient deprivation. For these 
reasons, AMPK is considered the leading actor in several 
pathologies such as obesity, diabetes, cachexia, and other 
metabolic disorders. Recently, increasing evidence sustains a 
key role for AMPK also in brain physiopathology. AMPK is 
involved in a variety of neuronal processes, such as neuronal 
proliferation, differentiation, and synaptic transmission.
It is possible that alterations in AMPK activity could 
reflect in the development of neurological disorders (Figure 4). 
AMPK
Astrocyte
mTORC1
Aβ aggregates
Tau phosphorylation
nNOS
Bcl-2
mHTT
Neuron
p38/p53
ROS
Ca2+
Rb
Glycolysis
Lactate
acidosis
Gl
iom
a Stroke AD
PD
HD
Stroke
Neuroblastoma
Figure 4 AMPK is involved in the manifestation of neurological conditions.
Notes: AMPK activity in the brain: a) modulates the production of β-amyloid and the formation of neurofibrillary tangles in AD; b) upregulates the expression of the 
prosurvival gene Bcl-2, thus preventing neurotoxicity in HD; c) orchestrates the quality control of mitochondria in PD; d) exerts pivotal roles in ischemic stroke by 
regulating nNOS and lactate production in neurons and astrocytes; e) is involved in brain tumor initiation and progression by modulating the oncosuppressor proteins Rb 
and p53.71,73–75,77,79,81,84,85,87,90,95,101,102,107,108
Abbreviations: AMPK, AMP-activated protein kinase; AD, Alzheimer’s disease; HD, Huntington’s disease; PD, Parkinson’s disease; nNOS, nitric oxide synthase.
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The studies reviewed here highlight intriguing relationships 
between AMPK and neurological diseases such as stroke, 
AD, HD, PD, and brain tumors, whereas other findings show 
emerging roles for this protein kinase in the development of 
mental disabilities in genetic disorders. However, even though 
a great knowledge about the pathological role of AMPK in 
the brain has been reached, literature data is far from being 
convincing. AMPK does not show a unique behavior in neuro-
degenerative diseases, and both detrimental and protective 
roles have been hypothesized. Indeed, while AMPK activation 
mediates mHtt-induced toxicity in HD striatal neurons, it pre-
vents neuronal cell death and acts as a survival factor in PD. 
The role of AMPK is ambiguous in AD pathogenesis, as some 
reports indicate that AMPK activation is strongly associated 
with a reduction in amyloidogenesis, whereas other studies 
demonstrate that AMPK inhibition corrects the Aβ-induced 
impairments in LTP.74,78 In the same way, many studies have 
described the divergent evidence about the involvement of 
AMPK in brain tumors and ischemic stroke. The presence 
of contradictory results indicates that further investigations 
are needed to better dissect the molecular mechanisms link-
ing AMPK activity and the development of CNS diseases. 
A deep comprehension could provide useful information for 
designing novel and effective therapeutic strategies addressing 
a variety of neurological conditions.
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